Nov 9 (Reuters) - Crescita Therapeutics Inc CTX.TO :
* CRESCITA THERAPEUTICS™ REPORTS 2018 THIRD QUARTER RESULTS STRONG ROYALTY REVENUE AND ACHIEVEMENT OF FIRST PLIAGLIS US SALES MILESTONE POSITIVE ADJUSTED EBITDA OF $0.8M
* CRESCITA THERAPEUTICS INC - QTRLY TOTAL REVENUE WAS $4.5 MILLION COMPARED TO $2.7 MILLION IN CORRESPONDING QUARTER OF PRIOR YEAR
* CRESCITA THERAPEUTICS - TOTAL CASH UTILIZED DURING QUARTER WAS $0.9 MILLION, RESULTING IN ENDING CASH & CASH EQUIVALENTS BALANCE OF $8.2 MILLION AS AT SEPT 30
* CRESCITA THERAPEUTICS INC - QTRLY NET INCOME FROM CONTINUING OPERATIONS PER SHARE $0.02
* CRESCITA THERAPEUTICS INC - ALL FIGURES IN C$